Charles Swanton, FRCP, BSc, PhD, Francis Crick Institute, London, UK, discusses differences between the mechanisms involved in lung cancer initiation and lung cancer maintenance and progression, including data from the CANTOS (NCT01327846) and CANOPY (NCT03631199) trials, as well as potential novel therapeutic approaches. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть